ReviewMuscle & nerve2025
Multifocal Motor Neuropathy: A Narrative Review.
Review in Muscle & nerve, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The role of leukocyte p38 MAP kinase in immune-mediated peripheral polyneuropathies: distinct modulation by intravenous immunoglobulins.Journal of neurology · 2026Article
- Beyond ALS: split-hand syndrome in immune-mediated motor neuropathies.Journal of neurology · 2026Article
- Patterns of motor nerve demyelination and their prognostic significance in multifocal motor neuropathy.IBRO neuroscience reports · 2026Article
- Neuromuscular ultrasound of the brachial plexus: know-how, know-when.Clinical neurophysiology practice · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multifocal motor neuropathy (MMN) is an acquired autoimmune polyneuropathy that affects almost exclusively the motor nerve fibers. Typically seen in middle-aged adults, its predominant clinical feature is a chronically progressive asymmetric weakness that affects the distal upper extremities most significantly. Minor sensory symptoms, sensory examination findings or abnormal sensory nerve conduction studies can be seen in the lower extremities in a minority of patients. Electrodiagnostic studies reveal motor conduction blocks at noncompressible sites, and minor findings of other demyelinating features such as conduction slowing or temporal dispersion. Anti-GM1 antibody titers are elevated in less than half of MMN patients, and more recent studies suggest mechanisms including antibody-induced complement attack at the node of Ranvier with resulting ion channel dysfunction. Peripheral nerve magnetic resonance imaging and neuromuscular ultrasound often reveal non-uniform enlargement of the nerve roots, plexuses, or peripheral nerve segments, thus being useful in assisting diagnosis. The differential diagnosis of MMN mainly includes motor neuron disease or demyelinating sensorimotor polyneuropathies. Immunoglobulin therapy is the first-line and mainstay of treatment, being effective in maintaining or restoring muscle strength in the majority of patients. However, motor strength often slowly declines over the long term, even with maintenance immunoglobulin treatment. More effective immunotherapy is needed to halt the slow progression of MMN, and complement inhibition appears to be a promising option in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.